Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Risk Factors for Carbapenem-resistant Acinetobacter Baumannii

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00462579
First received: April 17, 2007
Last updated: December 16, 2015
Last verified: December 2015

April 17, 2007
December 16, 2015
April 2007
December 2016   (final data collection date for primary outcome measure)
dead or alive [ Time Frame: end of study ] [ Designated as safety issue: No ]
health status
Not Provided
Complete list of historical versions of study NCT00462579 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Risk Factors for Carbapenem-resistant Acinetobacter Baumannii
Risk Factors for Carbapenem-resistant Acinetobacter Baumannii
It has been demonstrated that panresistant strains of Acinetobacter species may be selected by antibiotic use [4], may be transmitted from person to person [5], and may be passed via environmental contamination [6]. Surveillance for panresistant Acinetobacter species should be a priority, given the lack of antibiotic options for the treatment of these infections. There are currently no data on the antibiotic susceptibility of Acinetobacter species or on the rates of panresistant organisms. The elucidation of potential risk factors for resistant strains of Acinetobacter is therefore an important task, and the use of alternative antibiotics should be considered in ICUs where these strains are endemic.
The elucidation of potential risk factors for resistant strains of Acinetobacter is therefore an important task, and the use of alternative antibiotics should be considered in ICUs where these strains are endemic.he following information will be collected: age, sex, occupation, hospital location at the time of positive culture (ER, medical ward, ICU etc), date of positive culture, prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 30 days of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history. We will collect information retrospectively.
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample
carbapenem-resistant acinetobacter baumannii positive cultures
Acinetobacter Infections
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
100
December 2016
December 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Positive cultures of carbapenem-resistant acinetobacter baumannii

Exclusion Criteria:

  • Not meeting inclusion criteria
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00462579
PRO07040057
Yes
Not Provided
Not Provided
University of Pittsburgh
University of Pittsburgh
Not Provided
Principal Investigator: David L Paterson, MD University of Pittsburgh
University of Pittsburgh
December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP